Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
Advanced Enzyme's net profit margin of 22.2% in FY2026 reflects excellent profitability, with operating margin at 28.7% and gross margin at 75.3%.
In FY 2026, Advanced Enzyme posted a gross margin of 75.3%, an operating margin of 28.7%, a net margin of 22.2%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Advanced Enzyme's revenue grew 22.6% to 7.81B and net profit grew 32.4% to 1.74B YoY in FY2026, indicating strong business momentum.
In FY 2026, Advanced Enzyme's revenue grew by 22.6% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Advanced Enzyme's ROE of 10.3% in FY2026 indicates moderate shareholder returns.
In FY 2026, Advanced Enzyme reported an ROE of 10.3%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Advanced Enzyme's FCF/NI ratio of 0.60x in FY2026 indicates FCF trailing profits — heavy capex or working capital needs may be a factor.
In FY 2026, Advanced Enzyme's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Advanced Enzyme's OCF/NI ratio of 0.90x in FY2026 indicates reasonable cash conversion from operations.
In FY 2026, Advanced Enzyme's operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Advanced Enzyme's current ratio of 9.78x in FY2026 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2026, Advanced Enzyme reported a current ratio of 9.78. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Advanced Enzyme's interest coverage ratio of 85.2x in FY2026 indicates comfortable debt servicing capacity.
In FY 2026, Advanced Enzyme reported an interest coverage ratio of 85.2x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Advanced Enzyme's debt-to-equity ratio of 0.02x in FY2026 reflects a conservative, low-leverage capital structure.
In FY 2026, Advanced Enzyme reported a debt-to-equity ratio of 0.02. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Advanced Enzyme's debt decreased 18.7% YoY in FY2026 — positive deleveraging improves financial flexibility.
In FY 2026, Advanced Enzyme's total debt decreased by 18.7% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Advanced Enzyme's diluted shares remained virtually unchanged in FY2026.
Over 2 years (FY2025–FY2026), diluted shares remained essentially unchanged at 112.04M.
In FY 2026, Advanced Enzyme's diluted shares increased by 0.0% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2026